YLL545

a VEGF receptor 2 inhibitor with both anti-angiogenesis and antineoplastic activities; structure in first source

Also Known As:

1-(4-((1H-pyrazolo(3,4-d)pyrimidin-4-yl)oxy)phenyl)-3-(3-(trifluoromethyl)phenyl)urea

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Triple Negative Breast Neoplasms 07/05/2016 - "Here, we show that the novel VEGFR2 inhibitor YLL545 suppressed tumor angiogenesis and growth in triple-negative breast cancer without adverse effects. "
2.	Neoplasms (Cancer) 07/05/2016 - "YLL545 also inhibited proliferation and induced apoptosis in MDA-MB-231 breast cancer cells both in vitro and in vivo, and 50 mg/kg/d YLL545 inhibited human tumor xenograft growth by more than 50% in BALB/c nude mice. " 07/05/2016 - "Here, we show that the novel VEGFR2 inhibitor YLL545 suppressed tumor angiogenesis and growth in triple-negative breast cancer without adverse effects. "
3.	Breast Neoplasms (Breast Cancer) 07/05/2016 - "YLL545 also inhibited proliferation and induced apoptosis in MDA-MB-231 breast cancer cells both in vitro and in vivo, and 50 mg/kg/d YLL545 inhibited human tumor xenograft growth by more than 50% in BALB/c nude mice. " 07/05/2016 - "The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer."

1.	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)